Analyst Price Targets — BCAX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 12, 2026 12:06 pm | — | Morgan Stanley | $37.00 | $22.38 | TheFly | Bicara Therapeutics price target raised to $37 from $36 at Morgan Stanley |
| May 12, 2026 10:47 am | — | Goldman Sachs | $18.00 | $22.92 | TheFly | Bicara Therapeutics price target raised to $18 from $16 at Goldman Sachs |
| May 11, 2026 12:42 am | — | Guggenheim | $42.00 | $22.58 | TheFly | Bicara Therapeutics initiated with a Buy at Guggenheim |
| February 11, 2026 9:42 pm | Richard Law | Goldman Sachs | $14.00 | $14.80 | TheFly | Bicara moved to Neutral from Early-Stage Biotech at Goldman Sachs |
| January 8, 2026 12:03 pm | — | BTIG | $28.00 | $17.17 | TheFly | Bicara Therapeutics initiated with a Buy at BTIG |
| December 17, 2025 9:10 pm | Joseph Catanzaro | Mizuho Securities | $18.00 | $17.98 | TheFly | Bicara Therapeutics initiated with a Neutral at Mizuho |
| August 22, 2025 10:44 am | Robert Burns | H.C. Wainwright | $40.00 | $11.84 | TheFly | Bicara Therapeutics price target lowered to $40 from $41 at H.C. Wainwright |
| May 23, 2025 4:54 pm | Eva Fortea Verdejo | Wells Fargo | $8.00 | $9.27 | TheFly | Bicara Therapeutics upgraded to Equal Weight from Underweight at Wells Fargo |
| March 27, 2025 5:58 pm | — | Stifel Nicolaus | $48.00 | $13.40 | TheFly | Bicara Therapeutics price target raised to $48 from $47 at Stifel |
| October 8, 2024 5:56 am | Judah Frommer | Morgan Stanley | $35.00 | $24.45 | TheFly | Bicara Therapeutics initiated with an Overweight at Morgan Stanley |
Latest News for BCAX
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded inducement grants on July 1, 2026 to four new employees under Bicara's 2026 Inducement Plan as a material inducement to employment. The employees received, in the aggregate,…
CEO Claire Mazumdar sold 15,000 shares for a transaction value of approximately ~$301,000, based on a weighted average price of around $20.04 per share on May 18, 2026. This represented 3.98% of Mazumdar's direct holdings prior to the transaction, with post-transaction direct ownership at 362,152 shares.
Bicara Therapeutics Inc. (BCAX) Discusses New Clinical Data on Investigational Therapy for HPV Negative Head and Neck Cancer at ASCO Transcript
Bicara Therapeutics NASDAQ: BCAX said new data to be presented at the 2026 American Society of Clinical Oncology annual meeting support the clinical profile of ficerafusp alfa, also referred to by the company as Ficara, in first-line recurrent or metastatic HPV-negative head and neck cancer.
At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective analysis of standard of care
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BCAX.
U.S. House Trading
No House trades found for BCAX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.